Aptagen, LLC
S132B-C22 (ID# 7920)
RNA
Botulinum Neuroxin Type A (BoNT/A)
Protein
0.8 nM (reported value)
PBS, pH 7.4, 300mM NaCl, 3mM MgCl2, 5mM DTT, 1mg/ml BSA, 0.2% Tween, 1mg/ml heparin
NA If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.
rGprAprCprAprGprCprGpUrGprCprCpUrAprGprAprAprGpUrCprCprAprAprGprCpUUrAprAprApUrAprAprCprCprAprCprGprCpUrCprGprAprCprAprAprGprCp
40
12930.02
395100
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Tzuu-Wang Chang, Michael Blank, Pavithra Janardhanan, Bal Ram Singh, Charlene Mello, Michael Blind, Shuowei Cai, "In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin" Biochemical and Biophysical Research Communications 396 (2010) 854ƒ??860.
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.